RAU

RASAGILINE

Created:	2016-06-23
Last modified:	2017-05-31

Find Related PDB Entry
1 entries where RAU is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	26
Chiral Atom Count	1
Bond Count	27
Aromatic Bond Count	6

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	RASAGILINE
Systematic Name (OpenEye OEToolkits)	(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
Formula	C₁₂ H₁₃ N
Molecular Weight	171.238
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	C#CCN[CH]1CCc2ccccc12
SMILES	OpenEye OEToolkits	1.7.6	C#CCNC1CCc2c1cccc2
Canonical SMILES	CACTVS	3.385	C#CCN[C@@H]1CCc2ccccc12
Canonical SMILES	OpenEye OEToolkits	1.7.6	C#CCN[C@@H]1CCc2c1cccc2
InChI	InChI	1.03	InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
InChIKey	InChI	1.03	RUOKEQAAGRXIBM-GFCCVEGCSA-N

Drug Info: DrugBank

DrugBank ID	DB01367
Name	Rasagiline
Groups	approved
Description	Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Synonyms	Rasagilina Rasagiline mesylate Rasagiline tartrate (R)-indan-1-yl-prop-2-ynyl-amine RAS (1R)-N-propargylindan-1-amine Rasagiline (R)-N-2-Propynyl-1-indanamine
Brand Names	Jamp Rasagiline Rasagiline Rasagiline mesylate Asn-rasagiline Mint-rasagiline Rasagiline Mesylate Teva-rasagiline Rasagiline Mylan Rasagiline Ratiopharm Ag-rasagiline Azilect Apo-rasagiline
Indication	For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Categories	Agents that produce hypertension Agents that reduce seizure threshold Anti-Parkinson Drugs Antidepressive Agents Central Nervous System Agents Central Nervous System Depressants Compounds used in a research, industrial, or household setting Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 Substrates Dopamine Agents Drugs that are Mainly Renally Excreted Enzyme Inhibitors Hypotensive Agents Indenes Monoamine Oxidase B Inhibitors Monoamine Oxidase Inhibitors Nervous System Neuroprotective Agents Protective Agents Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome Serotonin Agents Serotonin Modulators
ATC-Code	N04BD02
CAS number	136236-51-6

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Amine oxidase [flavin-containing] B	MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQK...	unknown	inhibitor
Apoptosis regulator Bcl-2	MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFS...	unknown	activator
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682